Mina Ishidoya
Aomori, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Biweekly carboplatin plus nab-paclitaxel with concurrent radiotherapy followed by durvalumab consolidation for unresectable locally advanced non-small cell lung cancer: a real-world retrospective cohort study.
Journal: Translational lung cancer research
Published: February 09, 2026
The gut microbiota as a potential biomarker in patients with EGFR-mutant lung cancer.
Journal: Scientific reports
Published: May 16, 2025
Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301).
Journal: JTO clinical and research reports
Published: March 07, 2024
Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 10, 2024
Disseminated Non-tuberculous Mycobacteriosis with a Skull Lesion Controlled by Resection after Exacerbation during Antimicrobial Chemotherapy in a Patient Positive for Anti-IFN-γ-neutralizing Autoantibodies.
Journal: Internal medicine (Tokyo, Japan)
Published: December 03, 2023
Real-time MBDi-RPA using methyl-CpG binding protein 2: A real-time detection method for simple and rapid estimation of CpG methylation status.
Journal: Analytica chimica acta
Published: November 17, 2023
Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study.
Journal: Oncology letters
Published: June 16, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026